| D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review I Eljilany, AN Elzouki Vascular health and risk management, 455-462, 2020 | 152 | 2020 |
| Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries I Eljilany, F El-Dahiyat, LE Curley, ZUD Babar Expert Review of Pharmacoeconomics & Outcomes Research 18 (4), 403-414, 2018 | 18 | 2018 |
| Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review AM Fahmi, H Elewa, I El Jilany International Journal of Clinical Pharmacy 44 (3), 599-607, 2022 | 11 | 2022 |
| Cost-minimization analysis of ranibizumab versus aflibercept for treating Saudi patients with visual impairment owing to age-related macular degeneration or diabetic macular edema F El-Dahiyat, I Eljilany Value in Health Regional Issues 22, 23-26, 2020 | 8 | 2020 |
| Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey I Eljilany, A El-Bardissy, A Nemir, AN Elzouki, I El Madhoun, ... Journal of Thrombosis and Thrombolysis 50 (4), 957-968, 2020 | 6 | 2020 |
| Genetic polymorphism effect on warfarin–rifampin Interaction: a case report and review of literature M Salem, I Eljilany, A El-Bardissy, H Elewa Pharmacogenomics and Personalized Medicine, 149-156, 2021 | 5 | 2021 |
| Genetic and non-genetic factors impact on INR normalization in preprocedural warfarin management I Eljilany, M Elarref, N Shallik, AN Elzouki, L Bader, A El-Bardissy, ... Pharmacogenomics and Personalized Medicine, 1069-1080, 2021 | 4 | 2021 |
| Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management I Eljilany, H Elewa, D Al-Badriyeh Current problems in cardiology 48 (6), 101128, 2023 | 3 | 2023 |
| Periprocedural anticoagulation management of patients receiving warfarin in qatar: a prospective cohort study I Eljilany, M Elarref, N Shallik, AN Elzouki, AM Mohammed, B Shoman, ... Current Problems in Cardiology 46 (6), 100816, 2021 | 3 | 2021 |
| The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors CE Wheeler, SS Coleman IV, R Hoyd, L Denko, CHF Chan, ... bioRxiv, 2023 | 2 | 2023 |
| A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab I Kobeissi, I Eljilany, T Achkar, WA LaFramboise, L Santana-Santos, ... International journal of molecular sciences 24 (9), 8167, 2023 | 2 | 2023 |
| Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG … I Eljilany, A Noor, M Paravathaneni, I Yassine, SJ Lee, M Othus, J Moon, ... Cancers 15 (9), 2561, 2023 | 2 | 2023 |
| Bridging vs Non-Bridging with Warfarin Peri-Procedural Management: Cost and Cost-Effectiveness Analyses I Eljilany, H Elewa, O Abdelsamad, M Abdelgelil, A Mahfouz, R Al Anany, ... Current Problems in Cardiology 46 (11), 100839, 2021 | 2 | 2021 |
| A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset C Wang, A Ma, Y Li, ME McNutt, S Zhang, J Zhu, R Hoyd, CE Wheeler, ... Cancer research communications 4 (2), 293-302, 2024 | 1 | 2024 |
| Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field I Eljilany, E Castellano, AA Tarhini Cancers 15 (16), 4125, 2023 | 1 | 2023 |
| The dilemma of peri-procedural warfarin management: a narrative review I Eljilany, A El-Bardissy, H Elewa Clinical and Applied Thrombosis/Hemostasis 27, 10760296211012093, 2021 | 1 | 2021 |
| Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy AA Tarhini, I Eljilany, S Coleman, DJ Hedges, M McCarter, J Carpten, ... Cancer Research 84 (6_Supplement), 71-71, 2024 | | 2024 |
| Racial/Ethnic Disparities in Use of Angiotensin II Receptor Type 2/4 Stimulatory Vs. Inhibitory Antihypertensive Among Hypertensive Adults in the USA E Jafari, S Abuloha, A Alshehri, I Eljilany, R Aroza, J Guo, H Shao Journal of Racial and Ethnic Health Disparities, 1-10, 2024 | | 2024 |
| Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches AA Tarhini, E Castellano, I Eljilany The Cancer Journal 30 (2), 54-70, 2024 | | 2024 |
| 185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors X Wang, T Li, TI Shaw, S Yao, I Eljilany, MD McCarter, AR Naqash, ... Journal for immunotherapy of cancer 11 (Suppl 1), 2023 | | 2023 |
Hazem ElewaAssociate Professor, Head of Clinical Training, College of Pharmacy, Qatar UniversityVerified email at QU.edu.qa
